Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats.
about
Aldosterone antagonists for preventing the progression of chronic kidney diseaseAldosterone antagonists for preventing the progression of chronic kidney diseaseAldosterone antagonists for preventing the progression of chronic kidney diseaseAddition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathyPotential Renoprotective Agents through Inhibiting CTGF/CCN2 in Diabetic NephropathyModulation of Immunity and Inflammation by the Mineralocorticoid Receptor and AldosteroneDrospirenone and its antialdosterone propertiesAldosterone as a determinant of cardiovascular and renal dysfunctionActions of aldosterone in the cardiovascular system: the good, the bad, and the ugly?Aldosterone and vascular damage.Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis.Intact female stroke-prone hypertensive rats lack responsiveness to mineralocorticoid receptor antagonists.The spironolactone renaissance.New insights into the renin-angiotensin system and hypertensive renal disease.The promise of selective aldosterone receptor antagonists for the treatment of hypertension and congestive heart failure.Pharmacological manipulation of arachidonic acid-epoxygenase results in divergent effects on renal damage.Evolution and pathophysiology of chronic systolic heart failure.Critical blood pressure threshold dependence of hypertensive injury and repair in a malignant nephrosclerosis modelAldosterone antagonists in the treatment of hypertension and target organ damage.A multi-marker approach to predict incident CKD and microalbuminuriaImpact of aldosterone on vascular pathophysiology.Aldosterone-induced vasculopathy: a new reversible cause of cardiac death.Myeloid-specific deletion of the mineralocorticoid receptor reduces infarct volume and alters inflammation during cerebral ischemia.The importance of early intervention in CHF--signs and symptom relief.The pathophysiology of aldosterone in the cardiovascular system.Oxidative DNA damage in kidneys and heart of hypertensive mice is prevented by blocking angiotensin II and aldosterone receptors.Aldosterone does not mediate angiotensin II-induced atherosclerosis and abdominal aortic aneurysmsAldosterone and specific aldosterone receptor antagonists in hypertension and cardiovascular disease.Vascular inflammation and endothelial dysfunction in experimental hypertension.RAAS escape: a real clinical entity that may be important in the progression of cardiovascular and renal disease.Eplerenone prevents salt-induced vascular stiffness in Zucker diabetic fatty rats: a preliminary reportToward a broader understanding of aldosterone in congestive heart failure.Mineralocorticoid receptor blockade: new insights into the mechanism of action in patients with cardiovascular disease.Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatmentCan dual blockade of the renin-angiotensin system reduce progression of kidney disease beyond monotherapy?Role of the selective aldosterone receptor blockers in arterial hypertension.Eplerenone: will it have a role in the treatment of acute coronary syndromes?Spironolactone improves structure and increases tone in the cerebral vasculature of male spontaneously hypertensive stroke-prone ratsAldosterone blockade in cardiovascular disease.Antihypertensive drugs and the kidney.
P2860
Q24194979-C1827899-DB45-494F-9839-E3D2703FF6FDQ24239909-B5D63967-9C2E-4C7A-BB81-BCB0AF3080ECQ24243615-BD45959E-F9CA-4AC6-A7C0-1001400E8525Q24657470-5EBEFBF2-B9DD-4B28-AA65-AE464717A494Q26784039-404DBA0B-FC54-46FD-8890-D90CD88CDEF9Q26785911-C61FD105-3184-4037-BBCF-99AA2CAEDAC6Q28293272-06D5443B-16B6-4296-A312-99C1E664F95CQ28344356-1F5C8073-588D-4C7F-846C-6F99DF5C9709Q30319286-FF34C073-C0A1-468B-BEA2-2C664D72651DQ33181046-B0FAA696-B2DA-42E9-A0A7-0CF284BDB79CQ33414957-5EDFB587-0990-40FB-A73E-715CF979DCC9Q33580961-E5129E06-29BE-45B1-8E8A-38AF3E92F91CQ33944169-0328488E-6BF4-4857-AE65-1D7E58B90426Q34028215-6BFFACB0-9CC6-45B4-AAEA-2C870782EE3AQ34028612-CF6F992C-4611-4BE6-B0AB-49381F1A68D7Q34049059-3A82DEC9-FE87-440B-9CBB-466B0B4D04D3Q34088198-BE78DA45-5E5E-4368-8644-AC9A0144FA34Q34173320-A7B7AF4F-5BC7-4BB2-9811-1682E147E5F5Q34251366-46A51FF8-B968-47C5-9530-640E8D5B160DQ34457191-4D21B0DB-5AF2-4D24-839B-235BCD365EB8Q34513179-0C261504-AC18-45BF-A89A-6EFD30BD3217Q34553636-572BAE1B-AC62-48B0-91AC-C03E6F009FF0Q34591546-128AF3E6-159C-4401-9B25-38725691E2C1Q34610087-82903366-A04A-4B1F-B2F0-790EB611C1B2Q34967661-616AA19C-3BEF-43BB-85C5-52A519FB606FQ34978108-04F47D45-0379-44E4-B2BA-35EACA623099Q35048624-707EDB08-FA93-40FF-A86F-34BD42AB34B2Q35087008-EF9F1BAC-800F-4AA0-905B-DC1EDC945618Q35207893-9E429719-9F59-43DB-8A92-4C6923B65CBBQ35209084-9A377B3C-4754-4B8D-81DA-CD47718CDF99Q35554847-2458AC88-5C0C-425F-A8A8-EDB122236190Q35580139-E0471995-FCD8-4F12-9B29-08EF3C2E9D60Q35580143-BF70DC4F-358C-4077-9726-BC0EFD955A53Q35582571-2F07F1D5-8FD1-42E6-BFA0-4EB2D6FE306DQ35609741-4C4DF4E4-8AA7-4FA5-823A-3EB7B463FF0CQ35770241-37684553-2FAD-477F-9A12-8BA580D21CB9Q35795323-784EEBDD-1C0C-4AD8-B201-A0B10BB40296Q35878810-13CB97B0-419C-4E6B-95CD-10CB5558126DQ35887602-174B261E-6729-4EF9-B7F0-A53BE9DF5188Q35918820-78D8813D-102A-4912-815A-CDD8DCDA9FD7
P2860
Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats.
@en
Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats.
@nl
type
label
Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats.
@en
Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats.
@nl
prefLabel
Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats.
@en
Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats.
@nl
P2093
P356
P1433
P1476
Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats.
@en
P2093
P304
P356
10.1161/01.HYP.31.1.451
P407
P433
P577
1998-01-01T00:00:00Z